Geneseeq, a Chinese genetic testing company that focuses on treatments for cancer, has raised RMB800 million ($115 million) in a funding round led by state-owned China Reform Holding Corporation.
Lilly Asia Ventures, SBCVC, Everest Venture Capital Investment, E Fund Management, and Swiss China Corporation also contributed capital. Geneseeq specializes in next-generation sequencing (NGS) for precision...
Warburg Pincus will sell an approximately 5.5% interest in Hong Kong-listed IVF services provider Jinxin Fertility for about HK$1.5 billion ($194 million) through a share placement.
CLSA, the international arm of China-based brokerage CITIC Securities, has launched a strategy to offer high net worth clients investment opportunities in late-stage private companies in Asia.
DCM Ventures has raised $880 million across two funds that will continue its early-stage technology strategy, with 70% of the capital earmarked for deployment in China.
Having previously focused on offshore IPOs, China managers with US dollar funds are now considering the Star Market. But going onshore means more regulation as well as high valuations